PAST ARTICLE SEARCH
Search Drug Discovery & DDS Articles
Find Drug Discovery & DDS coverage by technology, company, or a free keyword search.
626 published articles37 technology terms26 companies
Search by Technology
Select a technology term to view related Drug Discovery & DDS articles.
Search by Company
Select a company to view related Drug Discovery & DDS articles.
Keyword Search
Search titles and article content within Drug Discovery & DDS.
Results
Matching articles will appear here.
Select a technology term or company, or enter a keyword.
Latest articles in Drug Discovery & DDS
The 100 most recent articles. Use the search above to filter by technology, company, or keyword.
- Drug Discovery & DDS Weekly Report October 11, 20262026-10-11
- ConsiGma CDC Flex: Hovione’s 2026 US continuous tableting launch2026-10-11
- Ac-225: NorthStar Medical Technologies production and FDA specs2026-10-11
- Oral GLP-1 Agonists: FDA 2026 approval and manufacturing impact2026-10-11
- Enhertu: AstraZeneca and Daiichi Sankyo China approval timeline2026-10-11
- Ubamatamab: Regeneron’s MUC16×CD3 antibody 73% response specs2026-10-11
- Datroway: Daiichi Sankyo and AstraZeneca China approval 20262026-10-11
- GrowGen framework: Molecular generation specs via deep learning2026-10-11
- AI Chemists: ETH Zurich and Roche drug synthesis roadmap 20262026-10-11
- Oncopeptides PDC: Blood-brain barrier specs for brain tumors2026-10-11
- mRNA-LNP delivery explained: Georgia Tech’s 2026 oral vaccine2026-10-11
- Drug Discovery & DDS Weekly Report October 4, 20262026-10-04
- TEV-‘749: Teva’s subcutaneous olanzapine Phase 3 safety specs2026-10-04
- Pebrilzo: Biocon Biologics’ HER2 biosimilar EMA specs for 20262026-10-04
- Ionis Ulefnersen: P3 results for FUS-ALS and RNA specs 20262026-10-04
- Dapis Cyanobacteria: Dolastatin 15 anticancer source explained2026-10-04
- PD-(L)1×VEGF ADC: 87.5% ORR in SCLC patients at WCLC 20262026-10-04
- Oral GLP-1 Agonists: Weight loss and HbA1c efficacy explained2026-10-04
- Stanford Virtual Biotech: AI agents drug discovery specs 20262026-10-04
- Olpasiran: Novartis’ Phase 2b siRNA Lp(a) reduction results2026-10-04
- MIT LNP Technique: Organ-specific RNA delivery method explained2026-10-04
- Exosome Delivery: 6-fold Paclitaxel concentration for GBM specs2026-10-04
- NTS231: Nutshell Therapeutics’ AI-driven 24-month IND timeline2026-10-04
- ARO-DIMER-PA: Arrowhead’s Phase 1/2a siRNA knockdown specs2026-10-04
- Drug Discovery & DDS Weekly Report September 26, 20262026-09-26
- AlphaFold: 2,800+ AI viral protein structures explained2026-09-26
- UZEDY: Teva’s risperidone real-world data and cost specs2026-09-26
- Enicepatide: Roche’s Phase II results for diabetes and obesity2026-09-26
- SORT LNPs explained: Novel 5th lipid component for organ delivery2026-09-26
- FDA: Non-animal testing standard roadmap and 2030 timeline2026-09-26
- Sotyktu: Bristol Myers Squibb’s first oral TYK2 inhibitor FDA specs2026-09-26
- Elunetirom: Phase 2 AMPLIFY-BD trial results for bipolar depression2026-09-26
- LUNAR 2.0: Arcturus Therapeutics mRNA expression roadmap2026-09-26
- mRNA Vaccine LNP: South Korea’s 2026 organ targeting specs2026-09-26
- AI drug discovery: 80-90% Phase I success rate explained2026-09-26
- Orforglipron: Eli Lilly oral GLP-1 vs injectable efficacy2026-09-26
- Oral GLP-1 drugs: 2026 clinical trial bioavailability specs2026-09-26
- Drug Discovery & DDS Weekly Report September 20, 20262026-09-20
- Arbutus & Genevant Sue Federal Government for Patent Infringement on Moderna mRNA Vaccine LNP Components2026-09-20
- Korsana Biosciences Secures $380 Million in PIPE Financing to Advance Alzheimer’s Disease Pipeline2026-09-20
- Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth2026-09-20
- Evonik Breaks Ground on Biotechnology Expansion in Slovakia, Strengthening European Pharmaceutical Manufacturing Hub2026-09-20
- Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability2026-09-20
- Prelude Therapeutics Receives IND Clearance for Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer Phase 1 Study2026-09-20
- FDA Approves Multiple Novel Cancer Therapeutics, Including Multi-Selective RAS(ON) Inhibitor Daraxonrasib and Next-Gen ADCs for Difficult-to-Treat Cancers2026-09-20
- Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery2026-09-20
- OS Therapies Strengthens FDA & MHRA Alignment, Joins Project Orbis for OST-HER2 Metastatic Osteosarcoma Program2026-09-20
- WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development2026-09-20
- Nutshell Therapeutics’ NRF2 Molecular Glue Degrader NTS231 Clears FDA IND, Becomes China’s First and World’s Second to Enter Clinical Development2026-09-20
- Shilpa Biologicals Opens GMP Facility for ADC Manufacturing in India’s Pharmacit2026-09-20
- Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Cleared for Phase I Clinical Trial in Advanced Solid Tumors by China’s NMPA2026-09-20
- FDA Approves Vertex’s Zanvastro: First Disease-Modifying ASO Therapy for Alexander Disease2026-09-20
- Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 20262026-09-20
- Novel Bispecific Antibodies Pumitamig, PF-08634404, and INCA033890-303 Advance to Phase 3 in Colorectal Cancer Trials2026-09-20
- Google DeepMind’s AlphaFold 3 Achieves Unprecedented Accuracy in Predicting Molecular Interactions, Driving AI-Discovered Drugs to Phase III Trials2026-09-20
- Eli Lilly’s Foundayo® (Orforglipron) Receives FDA Approval as First Oral Non-Peptide GLP-1 Receptor Agonist, Demonstrates Significant Weight Loss and Cardiometabolic Improvement2026-09-20
- Ivonescimab Significantly Improves Overall Survival vs. Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC2026-09-20
- BioNTech Announces gotistobart Phase III Achieves Median OS of 18.5 Months in Squamous NSCLC at WCLC 20262026-09-20
- Novel Bispecific ADC ICP-B381, Targeting PSMA and STEAP1, Approved for Phase 1 Clinical Trials in China for Prostate Cancer; US IND Submission Underway2026-09-20
- Gan & Lee Pharmaceuticals Initiates Phase I Trial for Once-Weekly Oral GLP-1 Peptide GZC8072 in China, Targeting Obesity and Type 2 Diabetes2026-09-20
- Drug Discovery & DDS Weekly Report September 13, 20262026-09-13
- Eli Lilly’s Oral GLP-1 Agonist Orforglipron Shows Promising Weight Loss and Safety in Phase 2 Trials, Rivaling Injectables2026-09-13
- US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape2026-09-13
- Waterfall Scientific Wins Up to $54.5 Million from ARPA-H to Pioneer Continuous-Flow mRNA Manufacturing Platform2026-09-13
- Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease2026-09-13
- Catalent Secures $4.1B Refinancing, Fuels Major Expansion in Biologics and Oral Drug Manufacturing to Meet GLP-1 Demand2026-09-13
- Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications2026-09-13
- The Pharma AI Data Problem: Complex Clinical Trial Data Impedes AI Model Development and Deployment2026-09-13
- Recorna and Starna Therapeutics Partner to Advance RNA Gene Editing for Lung Diseases Leveraging STAR LNP Technology2026-09-13
- Insitro Appoints Hideo Makimura as Chief Medical Officer to Accelerate Transition from AI Drug Discovery to Clinical-Stage Company2026-09-13
- Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study2026-09-13
- Ribo Life Science’s siRNA Therapeutic Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients2026-09-13
- Daiichi Sankyo/AstraZeneca’s Datroway Receives US FDA Approval for First-Line Metastatic TNBC, EMA CHMP Gives Positive Opinion2026-09-13
- Tangram Therapeutics Advances TGM-312 to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial for MASH Treatment2026-09-13
- Silence Therapeutics’ PV Drug Divesiran Achieves 88% Response Rate in Phase 2, Advances to Phase 32026-09-13
- Gan & Lee’s First-in-Class AR PROTAC GLR2037 Receives NMPA Approval to Initiate Clinical Trials for Advanced Prostate Cancer2026-09-13
- First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations2026-09-13
- FDA Grants Breakthrough Therapy Designation to JBS-003 (18F-FMISO), First PET Tracer to Guide Radiation De-escalation in HPV-Positive Oropharyngeal Cancer2026-09-13
- Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications2026-09-13
- First-in-Class Bispecific ADC BL-B01D1 Shows Antitumor Activity in Phase Ib Trial for Relapsed Extensive-Stage Small Cell Lung Cancer2026-09-13
- Novel TROP2-Targeting ADC, hIMB1636-LDP-AE, Demonstrates Potent Antitumor Efficacy and Anti-Cancer Stem Cell Activity in Breast and Lung Cancers2026-09-13
- Ultragenyx Announces Promising Phase 3 ASPIRE Results for Apazunersen (GTX-102), an ASO Therapeutic for Angelman Syndrome2026-09-13
- Argo Biopharma Presents Positive Phase II Data for siRNA Therapeutic BW-20805 in Hereditary Angioedema, Demonstrates Significant Reduction in Attack Rate2026-09-13
- Soufflé Therapeutics Initiates Phase I/II Clinical Trial for Muscle-Targeted siRNA Conjugate SFL-0821 in FSHD2026-09-13
- Inhaled siRNA Therapy ARO-RAGE Confirms Safety, Tolerability, and Lung Target Engagement in Pulmonary Inflammation Trial2026-09-13
- Bepirovirsen Achieves 20% Functional Cure Rate in Chronic Hepatitis B, Approved in Japan, Filed in China, FDA PDUFA October 20262026-09-13
- Arrowhead’s siRNA Therapeutic Plozasiran Achieves Approximately 80% Triglyceride Reduction in Severe Hypertriglyceridemia Patients2026-09-13
- Ionis ASO Therapy Zanvastro Receives First-Ever FDA Approval for Alexander Disease, Demonstrates Significant Stabilization of Walking Speed2026-09-13
- Gamgee Leverages ChatGPT and AlphaFold to Design Personalized mRNA Cancer Vaccine for Dogs, Accelerating Clinical Trials with AI2026-09-13
- Superluminal Medicines Secures $60M for AI-Driven Rare Obesity Drug, Clinical Trials Expected This Year2026-09-13
- Isomorphic Labs and Recursion Pharmaceuticals Forge Major AI Drug Discovery Alliances with Pharma Giants2026-09-13
- Insilico Medicine’s AI-Designed Drug Rentosertib Shows Early Signs of Biological Age Reversal, Enters Phase III for Idiopathic Pulmonary Fibrosis2026-09-13
- Drug Discovery & DDS Weekly Report September 6, 20262026-09-06
- AI-Designed Drug Makes Human Debut: BigHat Biosciences Begins Clinical Trial for Gastric Cancer ADC2026-09-06
- Protein Accumulation Mechanism is Key to PROTAC Efficacy, Unlocking New Strategies for Refractory Cancers2026-09-06
- The Multispecific Antibody Revolution: Reshaping CDMOs for Next-Gen Biologics2026-09-06
- UBC Bolsters AI-Driven Drug Discovery and Protein Design with New Research Chairs2026-09-06
- Genentech and DualityBio Forge $1B+ Partnership to Accelerate Novel ADC Payloads, Combat Resistance2026-09-06
- Polymeric Nanoparticles Unlock New Frontiers in Drug Delivery, Gene Therapy, and Medical Imaging2026-09-06
- Logic-Gated Bispecific ADCs Break Toxicity Barrier, Unleash Thousands of New Cancer Targets2026-09-06